SPACInsider Logo
Act II Global Re-Files and Drops J.P. Morgan From the Cover
by Kristi Marvin on 2019-04-22 at 5:58pm

Act II Global Acquisition Corp. re-filed their amended S-1 tonight, with a few changes, large and small. The most noticeable change being the removal of their prior left lead – J.P. Morgan.  As noted previously, J.P. Morgan hasn’t been involved in a SPAC since 2017 and never as left lead.  So…we can speculate all sorts of reasons as to why J.P. Morgan is no longer involved in Act II, but the net result is, this is a nice coup for Cantor, who is now their sole book-runner.  J.P. Morgan is a great bank, but in SPAC Land it’s always advantageous to have a really experienced SPAC underwriter.  Perhaps JPM wouldn’t go to the right of Cantor.

Nonetheless, the other change to Act II’s IPO filing includes a small reduction of their at-risk capital from $7.0 million to $6.75 million.  Additionally, Cantor is using one of their standard plays from their playbook, where in the event of an over-allotment, management does not have to contribute additional at-risk capital.  This is because they are back loading the underwriter fees on the over-allotment.

Using Act II’s $250 million SPAC as an example, the upfront underwriting fee is 2% and the deferred fee is 3.5%.  However, if they exercise the full over-allotment for a total deal size of $287.5 million, normally, an underwriter would be paid 2% upfront on the additional $37.5 million over-allotment.  Instead, what Cantor does is not take any additional UPFRONT (2%) underwriting fees on the over-allotment of $37.5 million, but will instead collect 5.5% at the closing of the business combination on just the over-allotment portion and the $250 million will still be subject to a 3.5% fee. (If this is a little confusing, just compare the Use of Proceeds tables in the first and most recent S-1s.)  This enables the SPAC management team to not have to increase their private placement purchase (at-risk capital) in order to account for the additional upfront underwriting fees.

In any event, Act II was previously expected to price Wednesday, April 24th for trading Thursday, April 25th.  This schedule should remain the same, but we’ll update any further changes.

Act II revised summary of terms below:

Act II transaction terms 4-22-19


Recent Posts
by Kristi Marvin on 2023-03-25 at 12:14pm

Terms Tracker for the Week Ending March 24, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. While this week was relatively quiet on the filings front, we did see March’s second SPAC IPO price with Oak Woods Acquisition Corp’s $50 million...

by Marlena Haddad on 2023-03-24 at 5:40pm

Latest Non-Redemption Agreements: ExcelFin Acquisition Corp. ExcelFin Acquisition Corp. (XFIN) Adds Non-Redemption Agreement In connection with the special meeting of stockholders of ExcelFin Acquisition Corp. (NASDAQ:XFIN) to extend its completion deadline from April 25, 2023 to October 25, 2023, the company and its sponsor, ExcelFin SPAC LLC, entered into a non-redemption agreement with an unaffiliated third party....

by Marlena Haddad on 2023-03-24 at 11:33am

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News:  Momentus SPAC backers accused of deliberately engineering a catastrophic deal  Momentus SPAC Backers Accused of Hiding Disastrous Deal’s Flaws A Momentus Inc. (NASDAQ:MNTS) investor sued backers of its blank-check merger with a shell company,...

by Nicholas Alan Clayton on 2023-03-24 at 7:20am

DiamondHead Holdings Corp. (NASDAQ:DHHC) announced in an 8-K this morning that its shareholders approved its combination with Great Southern Homes at a special meeting March 23. Only 109,426 shares were redeemed in the connection with the vote, but DiamondHead has seen about 87% redemptions in total across all previous votes, leaving it with about $43.9...

by Nicholas Alan Clayton on 2023-03-24 at 7:05am

Graf Acquisition Corp. IV (NYSE:GFOR) announced that it has signed a non-binding letter of intent to combine with clinical-stage biopharma company NKGen. This announcement is not a pure teaser as Graf IV is not facing an imminent extension vote and currently has until May 25 on its clock. It does, however, signal something of a...

Privacy Policy|Terms Of Use
Copyright © 2023 SPACInsider, Inc. All Rights Reserved